A bottle of diphenhydramine costs less than a cup of coffee, which explains why antihistamine sleep aids dominate pharmacy shelves and bedside cabinets. But pharmacologists and sleep researchers are raising a clear caution: the drowsiness these medications produce is not the same thing as restorative sleep, and nightly use carries risks that accumulate with every passing month.
First-generation antihistamines induce sedation by blocking histamine receptors involved in wakefulness — the same receptors the brain relies on to stay alert and attentive during the day. Sleep studies note that while people do fall asleep faster on the drugs, the architecture of that sleep is altered, and tolerance develops quickly, often within days to weeks, quietly pushing users toward higher and higher doses.
The bigger concern is the medications’ anticholinergic burden. Research linking long-term anticholinergic use to cognitive decline, dry mouth, urinary retention, constipation, and next-day grogginess has led geriatric guidelines to advise against these drugs for older adults in particular. Falls, memory complaints, and daytime impairment are additional documented risks, and interactions with other sedating medications can compound them significantly.
Occasional use is generally considered acceptable for otherwise healthy adults, specialists say, but a nightly habit is a signal to investigate the cause of the insomnia rather than mask it. Behavioral strategies such as consistent wake times, evening light management, and cognitive behavioral therapy for insomnia address the root problem without the receptor-level side effects that ride along with every dose.
